{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-018311","form_type":"8-K","ticker":"RLAY","cik":"0001812364","company_name":"Relay Therapeutics, Inc.","filed_at":"2022-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.130639+00:00","generated_at":"2026-06-23T11:16:16.172445+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Relay Therapeutics reports 88% interim ORR for RLY-4008 in FGFR2-fusion CCA at pivotal dose","bullets":["15 of 17 efficacy-evaluable patients at 70 mg QD achieved partial response (88% interim ORR); 14 confirmed, 1 unconfirmed.","13 of 15 responders remain on treatment; one patient resected with curative intent; two stable disease patients continue.","Across all doses/schedules, 24 of 38 FGFRi-naïve FGFR2-fusion CCA patients had partial response (63% interim ORR).","No Grade 4 or 5 adverse events; off-target toxicities (hyperphosphatemia, diarrhea) clinically insignificant.","Pivotal cohort enrollment expected to complete in H2 2023; initial non-CCA data and full dose escalation data expected in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-018311","json":"https://secwatch.observer/filing/0000950170-22-018311.json","markdown":"https://secwatch.observer/filing/0000950170-22-018311.md","text":"https://secwatch.observer/filing/0000950170-22-018311.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022018311/0000950170-22-018311-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1812364/000095017022018311/rlay-20220911.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T11:16:16.172445+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}